2018 Press Releases

Keyword Search
 
DateTitle  
20-Sep-2018ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer
LYON, France and CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first three patients have been enrolled in its pivotal Phase 3 clinical trial, named ‘TRYbeCA1’, evaluating its lead product candidate eryaspase for the treatment of second line metastatic pancreatic cancer. The TR... 
 Printer Friendly Version
13-Sep-2018ERYTECH to Attend Upcoming Investor Conferences
LYON, France, Sept. 13, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that members of its management team will present and host investor meetings at the following investor conferences in September 2018: Conference Details: Morgan Stanley Global Healthcare Conference Attendee: Gil Beyen, Chief Executive Offi... 
 Printer Friendly Version
10-Sep-2018ERYTECH Reports First Half of 2018 Financial Results and Provides Business Update
Conference call and webcast scheduled for Tuesday, September 11th at 2:30 pm CET/8:30 am EDT Strategic shift to development of eryaspase for solid tumors confirmed Phase 3 trial for eryaspase in second line pancreatic cancer initiated and open for patient enrollment Phase 2 trial in triple-negative breast cancer on track for start of patient enrollment in Q4 Cash position of €165 million ($193 million) as of June 30, 2018 LYON , France and CAMBRIDGE, Mass., Sept. 10, 2018 (... 
 Printer Friendly Version
06-Sep-2018ERYTECH to Host Second Quarter 2018 Conference Call and Business Update
(GLOBE NEWSWIRE via COMTEX) --LYON, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a second quarter 2018 conference call and webcast on Tuesday, September 11, 2018, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights. The call is accessible via the below te... 
 Printer Friendly Version
05-Sep-2018Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2018
ERN France, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2018 Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France Listing markets: Euronext Paris from Euronext (Market segment B -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com Date Total of... 
 Printer Friendly Version
17-Jul-2018ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 2018
LYON, France and CAMBRIDGE, Mass., July  17, 2018  (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018.At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including:                                      ... 
 Printer Friendly Version
24-Jun-2018ERYTECH Confirms Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia
(GLOBE NEWSWIRE via COMTEX) --- Focuses development efforts on solid tumor indications - Confirms planned launch of company-sponsored randomized Phase 2 trial in first-line pancreatic cancer, in addition to ongoing launch of Phase 3 trial in second-line pancreatic cancer. - Expands eryaspase production capacity in the United States and France - Plans to cease development in acute lymphoblastic leukemia (ALL), including withdrawal of  European Marketing Authorization Application (MAA) ... 
 Printer Friendly Version
20-Jun-2018ERYTECH to Present at JMP Securities Life Science Conference
(GLOBE NEWSWIRE via COMTEX) --LYON, France, June 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present at the JMP Securities Life Science Conference, June 20, 2018 at The St. Regis, New York, in New York City. Conference Details: - Conference:&nbs... 
 Printer Friendly Version
15-Jun-2018ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018
LYON, France, June 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present preclinical data on the enzymatic activity of eryaspase (GRASPA®) for the treatment of relapsed acute lymphoblastic leukemia (ALL) and results of its Phase 2b clinical trial evaluating eryaspase (GRASPA®) for the treatment ... 
 Printer Friendly Version
07-Jun-2018Erytech Pharma S.A. : General Meeting to be held on June 28, 2018 and Availability of Related Materials
LYON, France, June  07, 2018  (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced the availability of documents for its Annual General Meeting, to be held on June 28, 2018. ERYTECH shareholders are hereby informed of the A... 
 Printer Friendly Version
04-Jun-2018ERYTECH to Present Pharmacodynamic Data from Phase 2/3 Trial of Eryaspase in ALL at ASCO 2018
(GLOBE NEWSWIRE via COMTEX) --LYON, France, June 04, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present pharmacodynamic characterization data from its Phase 2/3 trial of eryaspase (GRASPA®) in combination with chemotherapy for the treatment of relapsed acute lymphoblastic leukemia (A... 
 Printer Friendly Version
30-May-2018ERYTECH to Webcast Presentation at the Jefferies Global Healthcare Conference
LYON, France--(BUSINESS WIRE)--May 30, 2018-- Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present at the Jefferies Global Healthcare Conference on Wednesday, June 6, 2018 at The Grand Hyatt, in New York City. ... 
 Printer Friendly Version
14-May-2018ERYTECH Reports First Quarter 2018 Financial Results and Provides Business Update
Conference call and webcast scheduled for Tuesday, May 15th at 2:30 pm CET/8:30 am EDT Finalized Phase 3 trial design for eryaspase in second line pancreatic cancer; on track for expected start of patient enrollment in Q3 Selected triple-negative breast cancer as the next solid tumor indication; preparing Phase 2 trial with expected start of patient enrollment in Q3 Reported pos... 
 Printer Friendly Version
14-May-2018ERYTECH Strengthens Executive Team with the Appointment of Alex Dusek as VP of Commercial Strategy
LYON, France--(BUSINESS WIRE)--May 14, 2018-- Regulatory News: ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it has appointed Alex Dusek as its Vice President Commercial Strategy and member of the executive team. Mr. Dusek brings 25 years of experience in market access, product mar... 
 Printer Friendly Version
09-May-2018ERYTECH to Host First Quarter 2018 Conference Call and Business Update
LYON, France--(BUSINESS WIRE)--May 9, 2018-- Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its 2018 first quarter conference call and webcast on Tuesday, May 15, 2018, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights. ... 
 Printer Friendly Version
03-May-2018Erytech: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – April 30, 2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--May 3, 2018-- Regulatory News: Erytech (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com Date ... 
 Printer Friendly Version
24-Apr-2018ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F
LYON, France--(BUSINESS WIRE)--Apr. 24, 2018-- Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2017 “Document de Référence” for the year ended Decemb... 
 Printer Friendly Version
16-Apr-2018Erytech: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – March 31, 2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Apr. 16, 2018-- Regulatory News: Erytech (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol : ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com Dat... 
 Printer Friendly Version
12-Apr-2018ERYTECH to Present Results from Phase I Trial of eryaspase in ALL and New Pre-clinical Data at AACR 2018
LYON, France--(BUSINESS WIRE)--Apr. 12, 2018-- Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present full results from its U.S. Phase I trial evaluating eryaspase (GRASPA®) in combination with chemotherapy for the treatment of acute lymphoblas... 
 Printer Friendly Version
13-Mar-2018ERYTECH to Webcast Presentation at the Cowen and Company 38th Annual Healthcare Conference
LYON, France--(BUSINESS WIRE)--Mar. 13, 2018-- Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present at the Cowen and Company 38th Annual Health Care Conference on Wednesday, March 14, 2018 at The Marriott Copley... 
 Printer Friendly Version
12-Mar-2018ERYTECH Provides Business Update and Reports Financial Results for Full Year 2017
Conference call and webcast on Tuesday, March 13th at 1:30 pm CET/8:30 am EDT Reported positive data from Phase 2b clinical trial of eryaspase in second-line metastatic pancreatic cancer Resubmitted the European Marketing Authorization Application (MAA) for eryaspase (GRASPA®) in relapsed and refractory acute lymphoblastic leukemia (ALL) Raised approximately €194 million ($226 million) in... 
 Printer Friendly Version
07-Mar-2018ERYTECH : Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –February 28, 2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Mar. 7, 2018-- Regulatory News: ERYTECH (Euronext: ERYP- Nasdaq: ERYP) Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol : ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com   ... 
 Printer Friendly Version
06-Mar-2018ERYTECH to Host Fourth Quarter and Full Year 2017 Conference Call and Business Update
LYON, France--(BUSINESS WIRE)--Mar. 6, 2018-- Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its fourth quarter and full year 2017 conference call and webcast on Tuesday, March 13, 2018, at 1:30 PM CET/8:30 AM EST to discuss operational high... 
 Printer Friendly Version
13-Feb-2018ERYTECH Selects Triple Negative Breast Cancer as Next Indication for Eryaspase
Set-up activities for Phase 2 clinical study ongoing and patient enrollment expected to start Q3 2018 LYON, France--(BUSINESS WIRE)--Feb. 13, 2018-- Regulatory News: ERYTECH Pharma (Euronext: ERYP- Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the selection of Triple Negative Breast Cancer as the ne... 
 Printer Friendly Version
12-Feb-2018Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – January 31, 2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Feb. 12, 2018-- Regulatory News: Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol : ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com ... 
 Printer Friendly Version
08-Feb-2018ERYTECH to Present at the 2018 BIO CEO & Investor Conference
ERYTECH to Present at the 2018 BIO CEO & Investor Conference LYON, France - February 8, 2018 - ERYTECH Pharma (Euronext Paris: ERYP, Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen, Chief Executive Officer, will present at the 2018 BIO CEO & Investor Conference, being held February 12-13, 2018 at the New York Marriott Marquis in New York City.... 
 Printer Friendly Version
08-Jan-2018Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –December 31, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Jan. 8, 2018-- Regulatory News: Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol : ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com ... 
 Printer Friendly Version
Top